Search

Your search keyword '"Mavroudis, Dimitrios"' showing total 682 results

Search Constraints

Start Over You searched for: Author "Mavroudis, Dimitrios" Remove constraint Author: "Mavroudis, Dimitrios"
682 results on '"Mavroudis, Dimitrios"'

Search Results

1. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

3. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

4. Rare germline copy number variants (CNVs) and breast cancer risk

5. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

6. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

7. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.

8. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

9. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

10. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association ConsortiumBreast Cancer Risk Factors and Survival By Tumor Subtype

11. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

12. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

13. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

14. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

15. The impact of coding germline variants on contralateral breast cancer risk and survival

16. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

17. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

19. Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer.

20. LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer

24. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

25. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

26. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction

27. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla TM platform: a real-world two-center experience in Greece

28. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project

29. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset

30. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

31. Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis.

33. Real-world management practices and characteristics of patients with advanced melanoma initiated on immunooncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project

34. Retroperitoneal Soft Tissue Sarcoma: Emerging Therapeutic Strategies

35. Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

36. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

37. Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy

38. Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study

39. Genome-wide association study of germline variants and breast cancer-specific mortality

40. Skin toxicity of enfortumab vedotin: proposal of a specific management algorithm

41. Current Cardioprotective Strategies for the Prevention of Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients

42. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

44. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform: a real-world two-center experience in Greece.

45. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

46. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

47. Clinical Outcomes Beyond 1LEGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’

48. Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors

49. Figure S1, Figure S2, Table S1 from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors

Catalog

Books, media, physical & digital resources